Cargando…
Neuropharmacology in traumatic brain injury: from preclinical to clinical neuroprotection?
Traumatic brain injury (TBI) constitutes a major health problem worldwide and is a leading cause of death and disability in individuals, contributing to devastating socioeconomic consequences. Despite numerous promising pharmacological strategies reported as neuroprotective in preclinical studies, t...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290810/ https://www.ncbi.nlm.nih.gov/pubmed/33527472 http://dx.doi.org/10.1111/fcp.12656 |
_version_ | 1784748996654268416 |
---|---|
author | Lerouet, Dominique Marchand‐Leroux, Catherine Besson, Valérie C. |
author_facet | Lerouet, Dominique Marchand‐Leroux, Catherine Besson, Valérie C. |
author_sort | Lerouet, Dominique |
collection | PubMed |
description | Traumatic brain injury (TBI) constitutes a major health problem worldwide and is a leading cause of death and disability in individuals, contributing to devastating socioeconomic consequences. Despite numerous promising pharmacological strategies reported as neuroprotective in preclinical studies, the translation to clinical trials always failed, albeit the great diversity of therapeutic targets evaluated. In this review, first, we described epidemiologic features, causes, and primary and secondary injuries of TBI. Second, we outlined the current literature on animal models of TBI, and we described their goals, their advantages and disadvantages according to the species used, the type of injury induced, and their clinical relevance. Third, we defined the concept of neuroprotection and discussed its evolution. We also identified the reasons that might explain the failure of clinical translation. Then, we reviewed post‐TBI neuroprotective treatments with a focus on the following pleiotropic drugs, considered “low hanging fruit” with high probability of success: glitazones, glibenclamide, statins, erythropoietin, and progesterone, that were largely tested and demonstrated efficient in preclinical models of TBI. Finally, our review stresses the need to establish a close cooperation between basic researchers and clinicians to ensure the best clinical translation for neuroprotective strategies for TBI. |
format | Online Article Text |
id | pubmed-9290810 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92908102022-07-20 Neuropharmacology in traumatic brain injury: from preclinical to clinical neuroprotection? Lerouet, Dominique Marchand‐Leroux, Catherine Besson, Valérie C. Fundam Clin Pharmacol Review Articles Traumatic brain injury (TBI) constitutes a major health problem worldwide and is a leading cause of death and disability in individuals, contributing to devastating socioeconomic consequences. Despite numerous promising pharmacological strategies reported as neuroprotective in preclinical studies, the translation to clinical trials always failed, albeit the great diversity of therapeutic targets evaluated. In this review, first, we described epidemiologic features, causes, and primary and secondary injuries of TBI. Second, we outlined the current literature on animal models of TBI, and we described their goals, their advantages and disadvantages according to the species used, the type of injury induced, and their clinical relevance. Third, we defined the concept of neuroprotection and discussed its evolution. We also identified the reasons that might explain the failure of clinical translation. Then, we reviewed post‐TBI neuroprotective treatments with a focus on the following pleiotropic drugs, considered “low hanging fruit” with high probability of success: glitazones, glibenclamide, statins, erythropoietin, and progesterone, that were largely tested and demonstrated efficient in preclinical models of TBI. Finally, our review stresses the need to establish a close cooperation between basic researchers and clinicians to ensure the best clinical translation for neuroprotective strategies for TBI. John Wiley and Sons Inc. 2021-03-13 2021-06 /pmc/articles/PMC9290810/ /pubmed/33527472 http://dx.doi.org/10.1111/fcp.12656 Text en Fundamental & Clinical Pharmacology© 2021 The Authors. Fundamental & Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of Société Française de Pharmacologie et de Thérapeutique. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Review Articles Lerouet, Dominique Marchand‐Leroux, Catherine Besson, Valérie C. Neuropharmacology in traumatic brain injury: from preclinical to clinical neuroprotection? |
title | Neuropharmacology in traumatic brain injury: from preclinical to clinical neuroprotection? |
title_full | Neuropharmacology in traumatic brain injury: from preclinical to clinical neuroprotection? |
title_fullStr | Neuropharmacology in traumatic brain injury: from preclinical to clinical neuroprotection? |
title_full_unstemmed | Neuropharmacology in traumatic brain injury: from preclinical to clinical neuroprotection? |
title_short | Neuropharmacology in traumatic brain injury: from preclinical to clinical neuroprotection? |
title_sort | neuropharmacology in traumatic brain injury: from preclinical to clinical neuroprotection? |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290810/ https://www.ncbi.nlm.nih.gov/pubmed/33527472 http://dx.doi.org/10.1111/fcp.12656 |
work_keys_str_mv | AT lerouetdominique neuropharmacologyintraumaticbraininjuryfrompreclinicaltoclinicalneuroprotection AT marchandlerouxcatherine neuropharmacologyintraumaticbraininjuryfrompreclinicaltoclinicalneuroprotection AT bessonvaleriec neuropharmacologyintraumaticbraininjuryfrompreclinicaltoclinicalneuroprotection |